Trials / Completed
CompletedNCT05148689
A Study Comparing Oxymetazoline 1% Cream to RHOFADE
A Double-blind, Randomized, Placebo Controlled Study, Comparing Oxymetazoline 1% Cream TO RHOFADE in the Treatment of Moderate to Severe Persistent Facial Erythema Assocoated With Rosacea
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 82 (actual)
- Sponsor
- Sun Pharmaceutical Industries, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
randomized, double-blind, placebo controlled
Detailed description
Subjects in this randomized, double-blind, placebo controlled study will be randomly assigned to treatment sequences with the test product, reference product or placebo control.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Oxymetazoline hydrochloride Cream, 1% | Cream |
| DRUG | Rhofade™ (oxymetazoline) cream, 1% | cream |
| DRUG | Placebo | cream |
Timeline
- Start date
- 2018-02-23
- Primary completion
- 2019-03-21
- Completion
- 2019-05-31
- First posted
- 2021-12-08
- Last updated
- 2021-12-08
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT05148689. Inclusion in this directory is not an endorsement.